This CME program will provide clinicians with an update regarding the safety and efficacy of JAK inhibitor therapeutics for the treatment of atopic dermatitis. The expert faculty, led by Dr. Lawrence F. Eichenfield, will first outline current clinical trial data for JAK-1 inhibitor therapeutics in atopic dermatitis (AD), encompassing topics such as difficulties living with AD and the unmet needs for patients. Following, further data regarding JAK inhibitors, and the duality of immunomodulation versus immunosuppression will be presented from the allergist’s perspective, and clinical relevance debated among the panel. To conclude, the faculty will analyze data presented at the American Academy of Dermatology 2022 Annual Meeting in a discussion-based format. Upon completion of this activity, learners will be better equipped to treat and manage their patients with atopic dermatitis.
Dermatologists, allergists, and other healthcare professionals involved in the management of patients with atopic dermatitis
Review and analyze new and emerging data for advanced therapies to treat patients with atopic dermatitis, including data presented at AAAAI 2022 and AAD 2022
Apply information from AAAAI 2022 and AAD 2022 to update risk/benefit profiles of JAK inhibitor therapeutics for atopic dermatitis
Understand the role of COVID-19 vaccination in the care of patients with atopic dermatitis, especially those receiving treatment with JAK inhibitors and other immunosuppressive agents
Review of JAK Inhibitor Therapeutics and Analysis of Unmet Needs for Patients with Atopic Dermatitis
New and Emerging Data, Including Data Presented at AAD 2022
Updating Risk/Benefit Profile, COVID-19 and JAK Inhibitors of New Trial Data & Therapeutics
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Lawrence F. Eichenfield, MD (Program Chair) | Consultant/Advisor: AbbVie Inc.; Almirall; Amgen Inc; Arcutis Biotherapeutics; Arena Pharmaceuticals; ASLAN Pharmaceuticals; Castle Creek Biosciences, Inc.; DERMATA THERAPEUTICS, INC.; Dermavant Sciences, Inc.; Eli Lilly and Company; Forte Biosciences, Inc.; Galderma; Ichinos Sciences; Incyte Corporation; Janssen Global Services, LLC; LEO Pharma A/S; Novartis; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; Union Therapeutics
Grant/Research Support: AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Galderma; Incyte Corporation; Ortho Dermatologics; Pfizer Inc.; Verrica Pharmaceuticals Speaker’s Bureau: LEO Pharma A/S; Novartis; Incyte Corporation; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme Stockholder: DERMATA THERAPEUTICS, INC.; Forte Biosciences, Inc.; Verrica Pharmaceuticals |
| Bob Geng, MD
|
Consultant/Advisor: Galderma; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme
Grant/Research Support: Regeneron Pharmaceuticals Inc.; Sanofi Genzyme Speaker’s Bureau: Regeneron Pharmaceuticals Inc.; Sanofi Genzyme |
| Eric Simpson, MD, MCR | Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN Pharmaceuticals; BenevolentAI; BiomX; Bluefin Biomedicine; Boehringer Ingelheim International GmbH; Boston Consulting Group; Collective Acumen LLC; Coronado Biosciences; Corevita Health Inc.; Dermira, Inc.; Eli Lilly and Company; Evidera; Excerpta Medica; Forte Biosciences, Inc.; Galderma; GlaxoSmithKline; Incyte Corporation; Janssen Global Services, LLC; Kyowa Kirin Co., Ltd; LEO Pharma A/S; Medscape, Inc; Merck & Co., Inc.; Novartis; Ortho Dermatologics; Pfizer Inc.; Physicians World, LLC; Pierre Fabre group; Regeneron Pharmaceuticals Inc.; Roivant Sciences Ltd; Sanofi Genzyme; SPARC; Trevi Therapeutics; Valeant Pharmaceuticals; WebMD LLC
Grant/Research Support: AbbVie Inc.; Amgen Inc; Arcutis Biotherapeutics; ASLAN Pharmaceuticals; Corevita Health Inc.; Dermira, Inc.; Eli Lilly and Company; Incyte Corporation; Kyowa Kirin Co., Ltd; LEO Pharma A/S; Novartis; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; SPARC; Trevi Therapeutics Speaker’s Bureau: AbbVie Inc.; Eli Lilly and Company; LEO Pharma A/S; Medscape, Inc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; Chelsey Benedek and Emma Boring hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 1.75 AMA PRA Category 1 Credits TM.
Clinicians should only claim credit commensurate with the extent of their participation.
This activity has been supported by independent educational grants from Incyte Corporation and Pfizer Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Incyte Corporation and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606